On December 23, the General Office of the National Development and Reform Commission released the 2019 evaluation results of the National Enterprise Technology Center. Among 1,563 participating companies, CSPC was rated as "excellent" with a score of 91.3, ranking it among the best in the industry. .
As the highest level of China's enterprise technology center rating, the National Enterprise Technology Center is jointly identified and guided by the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs, and the State Administration of Taxation. Leading large-scale demonstration and qualified enterprise technology centers are recognized, encouraging and guiding key enterprises in the industry to promote industrial technological progress and innovation capabilities, giving play to the leading role of enterprises in technological innovation, and establishing and perfecting the mechanism and mechanism of enterprise-led industrial technology research and innovation.
CSPC Holdings Group Co., Ltd. is a national innovative enterprise integrating R & D, production and sales of innovative drugs. It has 8 national R & D platforms, 6 provincial R & D platforms, and 376 valid invention patents. In the past three years, 18 international, national and industry standards have been presided over and participated in the formulation, and 175 R & D projects have been carried out by enterprises.
At present, CSPC has established an integrated R & D system at home and abroad, with R & D and clinical centers in Shijiazhuang, Beijing, and Shanghai, and clinical offices in Wuhan, Shenyang, and other eight cities; California, Texas, and Texas There are R & D centers and clinical centers in four places, including New Zealand and New Jersey. The annual investment in R & D exceeds 2 billion yuan. At present, there are about 300 innovative drug product projects of the Group, including more than 50 macromolecular biomedicals under development, more than 40 small molecular new medicines, more than 20 new formulations, and more than 50 clinical research projects.
The evaluation of the National Enterprise Technology Center in 2019 is a recognition of CSPC's innovation strength. The dawn of 2020 is coming. CSPC will continue to strengthen innovation and become a globally respected and respected innovative pharmaceutical company. And work harder!